926.1500 5.95 (0.65%)
NSE Sep 25, 2025 10:55 AM
Volume: 13,099
 

926.15
0.65%
Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended